Temporal Associations of the SARS-CoV-2 NP Antigen and Anti-Spike Total Ig Levels with Laboratory Parameters in a Greek Cohort of Hospitalized COVID-19 Patients.
Adult
Aged
Aged, 80 and over
Antigens, Viral
/ immunology
COVID-19
/ epidemiology
Coronavirus Nucleocapsid Proteins
/ immunology
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Greece
/ epidemiology
Humans
Immunoglobulins
/ immunology
Male
Middle Aged
Pandemics
Prospective Studies
SARS-CoV-2
/ immunology
Journal
Canadian respiratory journal
ISSN: 1916-7245
Titre abrégé: Can Respir J
Pays: Egypt
ID NLM: 9433332
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
05
2021
revised:
14
08
2021
accepted:
02
09
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
29
10
2021
Statut:
epublish
Résumé
The direct effect of SARS-CoV-2 on the lungs results in increased hospitalization rates of patients with pneumonia. Severe COVID-19 patients often develop ARDS which is associated with poor prognosis. Assessing risk factors for COVID-19 severity is indispensable for implementing and evaluating therapeutic interventions. We investigated the temporal associations between the SARS-CoV-2 antigen (Ag), total Immunoglobulin (Ig) levels, and several laboratory parameters in hospitalized patients with varying degrees of COVID-19 severity. The SARS-CoV-2 nucleocapsid protein (NP) and total Ig Spike (S) protein-specific antibodies were determined for each patient with lateral flow assays through repeated sampling every two days. Hematological and biochemical parameters were evaluated at the same time points. 40 Greek COVID-19 patients (31 males, 9 females) with a median age of 59.50 ± 16.21 years were enrolled in the study. The median time from symptom onset to hospitalization was 8.0 ± 4.19 days. A significant negative correlation was observed between the SARS-CoV-2 Ag and total Ig levels. The temporal correlation patterns of the SARS-CoV-2 NP Ag and anti-S total Ig levels with laboratory markers varied among patients with differing degrees of COVID-19 severity. Severe-critical cases had lower SARS-CoV-2 Ag and increased total Ig levels as compared to mild-moderate cases. Distinct temporal profiles of the SARS-CoV-2 NP Ag and anti-S total Ig levels may distinguish different groups of COVID-19 severity.
Sections du résumé
Background
The direct effect of SARS-CoV-2 on the lungs results in increased hospitalization rates of patients with pneumonia. Severe COVID-19 patients often develop ARDS which is associated with poor prognosis. Assessing risk factors for COVID-19 severity is indispensable for implementing and evaluating therapeutic interventions. We investigated the temporal associations between the SARS-CoV-2 antigen (Ag), total Immunoglobulin (Ig) levels, and several laboratory parameters in hospitalized patients with varying degrees of COVID-19 severity.
Methods
The SARS-CoV-2 nucleocapsid protein (NP) and total Ig Spike (S) protein-specific antibodies were determined for each patient with lateral flow assays through repeated sampling every two days. Hematological and biochemical parameters were evaluated at the same time points.
Results
40 Greek COVID-19 patients (31 males, 9 females) with a median age of 59.50 ± 16.21 years were enrolled in the study. The median time from symptom onset to hospitalization was 8.0 ± 4.19 days. A significant negative correlation was observed between the SARS-CoV-2 Ag and total Ig levels. The temporal correlation patterns of the SARS-CoV-2 NP Ag and anti-S total Ig levels with laboratory markers varied among patients with differing degrees of COVID-19 severity. Severe-critical cases had lower SARS-CoV-2 Ag and increased total Ig levels as compared to mild-moderate cases.
Conclusions
Distinct temporal profiles of the SARS-CoV-2 NP Ag and anti-S total Ig levels may distinguish different groups of COVID-19 severity.
Identifiants
pubmed: 34621457
doi: 10.1155/2021/6590528
pmc: PMC8490794
doi:
Substances chimiques
Antigens, Viral
0
Coronavirus Nucleocapsid Proteins
0
Immunoglobulins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6590528Informations de copyright
Copyright © 2021 Erasmia Rouka et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Acad Emerg Med. 2021 Mar;28(3):306-313
pubmed: 33481307
J Infect. 2020 Oct;81(4):647-679
pubmed: 32592705
Int J Mol Med. 2004 Aug;14(2):311-5
pubmed: 15254784
Am J Trop Med Hyg. 2020 Dec 23;:
pubmed: 33357280
Elife. 2020 Sep 07;9:
pubmed: 32894217
J Hum Hypertens. 2021 Apr;35(4):304-307
pubmed: 33483621
Clin Chim Acta. 2020 Nov;510:170-176
pubmed: 32659224
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
PLoS One. 2021 Jan 26;16(1):e0245382
pubmed: 33497420
Sci Rep. 2020 Aug 20;10(1):14042
pubmed: 32820210
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32616597
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
Nature. 2021 Mar;591(7848):124-130
pubmed: 33494096
J Infect. 2021 Feb;82(2):e35
pubmed: 32810520
Clin Microbiol Infect. 2021 Feb;27(2):289.e1-289.e4
pubmed: 33031947
J Leukoc Biol. 2020 Jul;108(1):17-41
pubmed: 32534467
Inflamm Res. 2020 Dec;69(12):1181-1189
pubmed: 32918567
Gastroenterology. 2021 Jun;160(7):2435-2450.e34
pubmed: 33676971
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
Int Immunopharmacol. 2021 Jan;90:107233
pubmed: 33290963
Chin Med J (Engl). 2020 May 5;133(9):1087-1095
pubmed: 32358325
Front Med (Lausanne). 2020 Dec 09;7:585003
pubmed: 33363185
J Clin Lab Anal. 2021 Jan;35(1):e23644
pubmed: 33112011
Expert Rev Respir Med. 2020 Nov;14(11):1149-1163
pubmed: 32734777
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33536313
J Infect Dis. 2021 Apr 8;223(7):1132-1138
pubmed: 33388780
J Infect. 2020 Dec;81(6):979-997
pubmed: 32946917
Front Immunol. 2021 Mar 15;12:614436
pubmed: 33790892
Thorax. 2020 Nov;75(11):1009-1016
pubmed: 32839287
Infection. 2021 Feb;49(1):117-126
pubmed: 33231841